Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neoplasms 7Sarcoma 3Multiple Myeloma 3Leukemia 3Kidney Neoplasms 3Glioma 3Brain Neoplasms 3Waldenstrom Macroglobulinemia 2Sarcoma, Alveolar Soft Part 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Oligodendroglioma 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioblastoma 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Astrocytoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Myeloproliferative Disorders 1

Interventions

Gemcitabine 358Fluorouracil 94Oxaliplatin 81Capecitabine 74130-nm albumin-bound paclitaxel 71Albumin-Bound Paclitaxel 70Radiotherapy 67Leucovorin 58Irinotecan 49Erlotinib Hydrochloride 47Cisplatin 44Bevacizumab 31pembrolizumab 30Radiosurgery 30Docetaxel 26Taxes 24Nivolumab 24Cetuximab 24Pancreaticoduodenectomy 20Drug Therapy 17folfirinox 16Cyclophosphamide 16Radiation 15Ipilimumab 13Endoscopic Ultrasound-Guided Fine Needle Aspiration 13Surgical Procedures, Operative 12Sorafenib 12Paclitaxel 12Neoadjuvant Therapy 12irinotecan sucrosofate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Pancreatic Neoplasms × perifosine × Clear all
NCT00053924 2015-07-23

Perifosine in Treating Patients With Advanced Pancreatic Cancer

University Health Network, Toronto

Phase 2 Completed
Gastrointestinal

Pancreatic Neoplasms

NCT00059982 2013-06-24

Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡